Circulating endothelial and progenitor cells in age-related macular degeneration.

CONCLUSION: We reported higher levels of circulating endothelial cells in age-related macular degeneration patients in comparison with the control group, thereby supporting the hypothesis of an involvement of endothelial dysregulation in the age-related macular degeneration and a reduction of the endothelial progenitor cell level in neovascular age-related macular degeneration patients after three intravitreal injections of ranibizumab. PMID: 31328962 [PubMed - as supplied by publisher]
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research

Related Links:

TriPla Regimen: A new treatment approach for patients with neovascular age-related macular degeneration in the COVID-19 "era". Eur J Ophthalmol. 2020 Oct 07;:1120672120963448 Authors: Sacconi R, Borrelli E, Vella G, Querques L, Prascina F, Zucchiatti I, Bandello F, Querques G Abstract In the last months, a rapidly increasing number of people have been infected with severe acute respiratory syndrome coronavirus 2, the virus causing coronavirus disease 2019 (COVID-19). Due to the risk of cross-infections, the number of visits and injections was dramatically reduced in the last months, and the ...
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research
Hip Resurfacing (HR), although reducing in popularity, is still used in the younger male population. Excellent medium-term results have been published, however the use of metal on metal has reduced with increased awareness of adverse reactions to metal debris (ARMD). ARMD has been shown to often be clinically “silent” following large Head MoM total hip replacement (THR). The purpose of our study was to report the incidence of ARMD following HR with a minimum follow-up of 13 years.We performed a retrospective study of a consecutive series of patients who underwent HR between 1st January 2000 - 1st Aug ust 2005.
Source: The Journal of Arthroplasty - Category: Orthopaedics Authors: Source Type: research
CONCLUSIONS OCT-A can be reliably used in the assessmen t of GA in AMD patients with and without foveal sparing disease. For both groups, measurements are comparable to IR, en-face OCT and FAF, despite the fact that the latter recorded larger area of GA, mainly in the foveal sparing cases.
Source: Ophthalmic Research - Category: Opthalmology Source Type: research
This study aims to find out which tool, fundus autofluorescence (FAF) or spectral domain optical coherence tomography (SD-OCT), is more sensitive in detecting retinal pigment epithelium (RPE) demise overlying drusen and can, therefore, help predict geographic atrophy (GA) appearance in Age-Related Macular Degeneration (AMD). Methods: A single-site, retrospective, observational, longitudinal study was conducted. Patients with intermediate AMD (iAMD) (large (>125 μm) or intermediate (63-125 μm) drusen with hyper/hypopigmentation) with a minimum follow-up of 18 months were included. Drusen wi...
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
Authors: Gualino V, Fourmaux E, Grenet T, Zerbib J, Wolff B Abstract Intravitreal anti-vascular epithelial growth factor (anti-VEGF) injections have revolutionised the treatment of macular diseases, but can be stressful for the patient. We surveyed 904 patients receiving injections at 5 centres in France regarding their feelings toward anti-VEGF injections. The mean age was 77.4 years, and the injections were performed mostly for age related macular degeneration (72%). Half of the patients had previously received>10 injections, 35.6% had received 3-10 injections, and 14.2% had received
Source: Journal Francais d Ophtalmologie - Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research
Authors: Wang Z, Li M, Yao Y, Hu J, Tang J, Tang R, Piao Z, Qu J Abstract Purpose: To study the short-term anatomical and functional outcomes in patients with neovascular age-related macular degeneration (nAMD) who were previously treated with conbercept and switched to ranibizumab or bevacizumab due to persistent activity. Methods: This retrospective single-arm study included nAMD patients who were followed up for at least three months after switching from at least 3 monthly intravitreal conbercept injections to bevacizumab or ranibizumab for persistent choroidal neovascularization (CNV) activity. The demograp...
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
Conclusion: Our study suggests that PU.1 is a novel therapeutic target for AMD, and the regulation of PU.1 expression represents a potentially novel approach against excessive oxidative stress in Aβ-driven RPE injury.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
CONCLUSIONS: The chronicity of nAMD disease and its management highlights the importance of long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet, one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes. PMID: 33011683 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Br J Ophthalmol Source Type: research
Age-related macular degeneration (AMD) is a chronic eye condition that leads to permanent vision loss in the central visual field. AMD makes reading challenging and inefficient. People with AMD often find it d...
Source: BMC Ophthalmology - Category: Opthalmology Authors: Tags: Research article Source Type: research
In this study, we have investigated the effects of anti-VEGF treatment (bevacizumab, aflibercept) after long-term, repeated treatment on uptake, storage and subcellular localization. Methods: Experiments were conducted in primary porcine RPE cells in first passage and in ARPE-19 cell line. Cells were treated with 250 µg/ml bevacizumab, aflibercept, or, as a non-VEGF inhibiting antibody, rituximab once a week for 1 day, 7 days, 4 weeks and 12 weeks. Cell survival was evaluated with MTT assay. Uptake and localization of compounds was investigated with immunofluorescence microscopy. Selective intracellular protein s we...
Source: Ophthalmic Research - Category: Opthalmology Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Lucentis | Opthalmology | Ranibizumab Injection